Trial Profile

A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epcoritamab (Primary) ; Rituximab (Primary) ; Zanubrutinib (Primary)
Indications Follicular lymphoma; Marginal zone B-cell lymphoma
Focus Therapeutic Use

Most Recent Events

03 Jul 2025 Addition of Marginal zone lymphoma to indication, addition of Parallel to study design,addition of 1 more cohort and Primary endpoint of Complete Metabolic Response (CMR) Rate among patients with R/R MZL
03 Jul 2025 Planned End Date changed from 1 Mar 2029 to 1 Mar 2028.
03 Jul 2025 Planned primary completion date changed from 1 Mar 2027 to 1 Mar 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com